Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.470
+0.010 (0.68%)
At close: Oct 8, 2025, 4:00 PM EDT
1.510
+0.040 (2.72%)
After-hours: Oct 8, 2025, 7:08 PM EDT
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2024. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$1,293,837
Market Cap
3.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -1 | -10.00% |
| Dec 31, 2023 | 10 | 4 | 66.67% |
| Dec 31, 2022 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
REVB News
- 27 days ago - Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds - Accesswire
- 4 weeks ago - Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data - Accesswire
- 4 weeks ago - Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data - Accesswire
- 4 weeks ago - Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study - Accesswire
- 2 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025 - Business Wire
- 2 months ago - Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research - Business Wire
- 3 months ago - Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study - Business Wire
- 3 months ago - Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 - Business Wire